« Back to Record
Buisseret, L., Rottey, S., de Bono, J., Mossakowski, M., Delafontaine, B., Manickavasagar, T., Kotecki, N., Martinoli, C., Schneider, M., De Henau, O., Chevron, P., Lagerfelt, J., & Machiels, J. P. (2020). Abstract CT152: First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers. Cancer research, 80(16_Supplement), CT152-CT152. doi:10.1158/1538-7445.AM2020-CT152
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/369337



